Deciphering Developmental Disorders
New project aims to unlock genetic changes behind disorders in one in 100 births
A new nationwide project aimed at improving the care and diagnosis of developmental disorders and understanding their relation to the human genome is announced today. The Deciphering Developmental Disorders (DDD) Project aims to improve the diagnosis and care of children in the UK who fail to develop normally due to changes in their genetic makeup. Its goal is to collect comprehensive genomic data and from this develop clinical tools to unlock the genetic reasons for the developmental problems in these children.
Over the next five years, the scientists and clinicians behind DDD hope to recruit to the study up to 12,000 children who have a serious delay in their physical or mental development or are born with multiple malformations. By capturing information on genetic make-up and physical and mental characteristics, the research team aims to improve diagnosis of conditions that affect around one in a hundred births in the UK.
The project is a direct collaboration with all twenty-three of the NHS Clinical Genetics Services from across the UK together with the Wellcome Trust Sanger Institute. It will provide information for researchers and clinicians into rare chromosomal abnormalities and their possible role in disease. The project is supported by the Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the Department of Health.
“Over 6,000 babies are born each year with serious developmental disorders, often caused by very rare genetic abnormalities. By linking together the expertise in genomics at the Wellcome Trust Sanger Institute with the unique network of Clinical Genetics Services offered by the NHS, these families can directly benefit from the rapid growth in our understanding of the human genome.”
Dr Nigel Carter who leads the Deciphering Developmental Disorders project
Currently, only a small minority of children can be diagnosed: the clinician must recognise the pattern of symptoms and appearance of the child and supplement that with laboratory studies that are often limited to identifying large rearrangements in chromosomes or studying a single gene.
The latest methods that can detect chromosome changes that are invisible under the microscope are slowly being introduced into clinical practice. DDD will broaden experience with these methods, increasing knowledge to link genetic changes to symptoms.
DDD will analyse DNA samples from patients using powerful, high-resolution chip technology and next generation sequencing. The technology is more powerful than the screening methods currently used in clinical practice and should be able to identify rare genetic mutations including copy number variations (duplicated or missing sections of DNA in our genome), exon deletions and single base pair changes. The scale of the DDD project offers the potential to help scientists determine which of these candidate variants are connected to the patient’s condition.
In some cases, the particular characteristics being shown by the patient may only have been seen in a handful of cases previously. Usually, this would make diagnosis very difficult. However, by creating a national resource with such information available to the entire NHS genetics network, the researchers hope to enable doctors to make a rapid diagnosis of a patient’s developmental condition in as many as one in five cases.
Diagnosing developmental disorders is important for improving patient care. Children often undergo expensive and potentially ineffective investigations and despite this the majority remain without a diagnosis. A genetic diagnosis allows doctors to provide the child’s parents with information on care and management options and also to offer genetic counselling regarding risk to future offspring.
The database will also enable researchers to link particular characteristics, or ‘phenotypes’, to possible candidate genetic variants. In the long term, scientists hope that this may enable them to identify molecular targets for new treatments for some of these conditions.
“Deciphering Development Disorders offers a win-win-win to patients, clinicians and scientists alike. It could significantly improve our understanding and management of these rare conditions and provide new avenues of research into treatments for scientists to pursue.”
Dr Helen Firth Consultant Clinical Geneticist at Addenbrooke’s Hospital, Cambridge
The DDD project will enable a major expansion of DECIPHER – the DatabasE of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources – which was established in 2004 to facilitate clinical interpretation of genetic variation seen in patients. DECIPHER connects clinical centres across the globe, providing each centre with access to information on a much larger number of patients. This allows doctors working on different continents to diagnose a very rare condition by identifying genomic regions that are altered in children with similar clinical features.
“This is an important project, which I hope will help us to harness the latest techniques in genomics to identify the genetic causes of developmental disorders within the NHS.”
Professor Dame Sally C Davies Chief Medical Officer
An important aspect of the DDD is investigation of the ethical and social issues surrounding the clinical use of new genomic technologies. Not only will the study focus on the issues facing healthcare professionals in the implementation of these new diagnostic tests but also on the perceptions and expectations of patients and families.
“Importantly, the DDD project will also be carrying out research with patients and health professionals to identify and analyse the ethical issues likely to arise in the use of these tools and to work towards the development of appropriate models of good practice in the care of patients and their families.”
Professor Mike Parker Director of the Ethox centre, Oxford University and co-applicant on the DDD
Deciphering Development Disorders was funded under the Health Innovation Challenge Fund (HICF), a parallel funding partnership between the Wellcome Trust and the Department of Health. The funders are collaborating to stimulate the creation of innovative healthcare products, technologies and interventions, and facilitate their development for the benefit of patients in the NHS and beyond. The HICF operates a succession of thematic calls for proposals, each selected to focus on unmet needs in healthcare relevant to the NHS, and will support innovative developments that are within three to five years of launch or adoption. http://www.hicfund.org.uk
The Department of Health (DH) works to improve the health and well-being of people in England. The Department sets overall policy on all health issues and is responsible for the provision of health services through the National Health Service.
The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms and more than 90 pathogen genomes. In October 2006, new funding was awarded by the Wellcome Trust to exploit the wealth of genome data now available to answer important questions about health and disease.
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
14 Sep 2021
Evidence-based national policies are essential to curb local COVID-19 infections
By using genomic surveillance and mobile phone data, researchers have uncovered useful insights into the management of the COVID-19 pandemic in ...
10 Sep 2021
Wellcome Sanger Institute recognised as Charity Times finalist for outstanding contribution to pandemic response
Staff praised for dedication and excellence as they work to sequence coronavirus genomes, helping to shape the pandemic response